| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
NEWS |
As Genetic Tests Move Into the Mainstream, Challenges Await for Doctors and Patients
| The first 150 words of the full text of this article appear below. |
In the last decade, the list of gene mutations that have known associations with increased cancer risk has grown to more than two dozen. As more is learned about these susceptibility genes and as new ones are discovered, the promise of tailored treatments and preventive measures grows. But when it comes to testing for these genes, there are unique challenges in bringing these new tests into clinical practice for both the clinicians who order the tests and the insurance companies that pay for them.
One of the difficulties in designing clear guidelines for genetic testing is that there is no single defined protocol for testing as there is when, for example, a patient comes in with chest pains. Depending on the circumstances, cancer patients, family members, or even members of the general public may be the subject of a potential genetic test that can be initiated by primary care physicians,
Genetic Tests in Cancer and Possible Interventions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. P. Brooks, I. M. MacDonald, S. J. Tumminia, N. Smaoui, D. Blain, A. A. Nezhuvingal, and P. A. Sieving Genomics in the Era of Molecular Ophthalmology: Reflections on the National Ophthalmic Disease Genotyping Network (eyeGENE) Arch Ophthalmol, March 1, 2008; 126(3): 424 - 425. [Full Text] [PDF]
|
|